VERA: TRUTAKNA launches with strong efficacy, broad access, and robust early commercial traction
TRUTAKNA's commercial launch follows strong clinical data showing kidney function preservation and proteinuria reduction in IgA nephropathy. The product's premium pricing, broad label, and convenient dosing support a large market opportunity, with early launch metrics tracking well and further data…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.